The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-01

AUTHORS

C J Wikstrand, C J Reist, G E Archer, M R Zalutsky, D D Bigner

ABSTRACT

Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, due to the diffuse infiltrative nature of primary glial tumor cell growth. Whether ultimate effect moieties are immunoglobulins, fragments and/or their constructs with drugs, toxins, radionuclides, or immune cells, the specificity of effector: cell surface marker is crucial. This review describes the identification, immunologic characterization, and biologic behavior of a transmembrane tumor-specific altered growth factor receptor molecule which may well serve as a mediator of multiple immunotherapeutic approaches: the class III variant of the epidermal growth factor receptor, EGFRvIII. More... »

PAGES

148-58

Journal

TITLE

Journal of NeuroVirology

ISSUE

2

VOLUME

4

Related Patents

  • Anitbodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Anti-Egfrviii Antibodies And Uses Thereof
  • Methods Of Treating Epidermal Growth Factor Deletion Mutant Viii Related Disorders
  • Vaccine Compositions
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Use Of Anti-Egfr Antibodies In Treatment Of Egfr Mutant Mediated Disease
  • Specific Binding Proteins And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Programmable Protein Circuits In Living Cells
  • Antibodies To Egf Receptor Epitope Peptides And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibody Against Egfrviii And Use Thereof
  • Vaccine Compositions
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Anti-Egfrviii Antibodies And Uses Thereof
  • Anti-Egfrviii Antibodies And Uses Thereof
  • Binding Proteins Specific For Egfr Expressed On Tumor And Uses Thereof
  • Specific Binding Proteins And Uses Thereof
  • Egf Receptor Epitope Peptides And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Antibodies Directed To The Deletion Mutants Of Epidermal Growth Factor Receptor And Uses Thereof
  • Monoclonal Antibody 175 Targeting The Egf Receptor And Derivatives And Uses Thereof
  • Anti-B7-H3 Antibodies And Antibody Drug Conjugates
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.3109/13550289809114515

    DOI

    http://dx.doi.org/10.3109/13550289809114515

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1070986052

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9584952


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Microbiology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Neurosciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amino Acid Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antigens, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "ErbB Receptors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glioma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunohistochemistry", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Nude", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Microscopy, Fluorescence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.", 
              "id": "http://www.grid.ac/institutes/grid.189509.c", 
              "name": [
                "Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wikstrand", 
            "givenName": "C J", 
            "id": "sg:person.01121443024.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121443024.27"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Reist", 
            "givenName": "C J", 
            "id": "sg:person.01273435474.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273435474.61"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Archer", 
            "givenName": "G E", 
            "id": "sg:person.014005665777.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014005665777.05"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Zalutsky", 
            "givenName": "M R", 
            "id": "sg:person.01230736174.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230736174.47"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Bigner", 
            "givenName": "D D", 
            "id": "sg:person.013515206217.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013515206217.45"
            ], 
            "type": "Person"
          }
        ], 
        "datePublished": "1998-01", 
        "datePublishedReg": "1998-01-01", 
        "description": "Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, due to the diffuse infiltrative nature of primary glial tumor cell growth. Whether ultimate effect moieties are immunoglobulins, fragments and/or their constructs with drugs, toxins, radionuclides, or immune cells, the specificity of effector: cell surface marker is crucial. This review describes the identification, immunologic characterization, and biologic behavior of a transmembrane tumor-specific altered growth factor receptor molecule which may well serve as a mediator of multiple immunotherapeutic approaches: the class III variant of the epidermal growth factor receptor, EGFRvIII.", 
        "genre": "article", 
        "id": "sg:pub.10.3109/13550289809114515", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2634129", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2468932", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2465896", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2441054", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2634316", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1114176", 
            "issn": [
              "1355-0284", 
              "1538-2443"
            ], 
            "name": "Journal of NeuroVirology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "4"
          }
        ], 
        "keywords": [
          "epidermal growth factor receptor", 
          "immunotherapeutic approaches", 
          "growth factor receptor", 
          "class III variants", 
          "factor receptor", 
          "diffuse infiltrative nature", 
          "central nervous system", 
          "cell surface markers", 
          "tumor cell growth", 
          "cancer cell eradication", 
          "immunotherapeutic target", 
          "immune cells", 
          "infiltrative nature", 
          "biologic behavior", 
          "immunologic characterization", 
          "nervous system", 
          "neoplastic cells", 
          "cell eradication", 
          "surface markers", 
          "normal tissues", 
          "receptors", 
          "cell growth", 
          "receptor molecules", 
          "cells", 
          "sparing", 
          "immunoglobulin", 
          "EGFRvIII", 
          "drugs", 
          "eradication", 
          "mediators", 
          "variants", 
          "markers", 
          "tissue", 
          "toxin", 
          "review", 
          "effectors", 
          "specificity", 
          "target", 
          "specific recognition", 
          "identification", 
          "utilization", 
          "recognition", 
          "growth", 
          "fragments", 
          "radionuclides", 
          "constructs", 
          "approach", 
          "molecules", 
          "characterization", 
          "distinction", 
          "nature", 
          "system", 
          "behavior", 
          "moiety", 
          "primary glial tumor cell growth", 
          "glial tumor cell growth", 
          "ultimate effect moieties", 
          "effect moieties", 
          "specificity of effector", 
          "growth factor receptor molecule", 
          "factor receptor molecule", 
          "multiple immunotherapeutic approaches", 
          "III variant"
        ], 
        "name": "The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.", 
        "pagination": "148-58", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1070986052"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.3109/13550289809114515"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9584952"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.3109/13550289809114515", 
          "https://app.dimensions.ai/details/publication/pub.1070986052"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:00", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_263.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.3109/13550289809114515"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.3109/13550289809114515'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.3109/13550289809114515'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.3109/13550289809114515'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.3109/13550289809114515'


     

    This table displays all metadata directly associated to this object as RDF triples.

    219 TRIPLES      21 PREDICATES      105 URIs      95 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.3109/13550289809114515 schema:about N0c4f6fa5387a4867b15f30048c91cbfc
    2 N18c8c6c0ba874c5fb761e7ef0dc66e11
    3 N202177ade7b74d38b89b07b2f2fc744a
    4 N20c93655b5244d43aea31df0ba7af6e8
    5 N27f893b83a974c08ab5fc474876a300c
    6 N64bf6d5c2b1e4431ac0d39756a3a2a65
    7 N716aa7f2e81f4ed697f75529f12facb8
    8 N76260d334f6b474395217f2bab94e487
    9 N76ed725bd65d4cc9baf62362dfcf0aa1
    10 N79cc634ea3c04a1b83ac80eba0cf26ee
    11 N9c1fc5014528453cb7f6042c9b3cf638
    12 Nc610f6d282984f4fa20d94ddcf728d9e
    13 Ne332b1aebde7470e8ef27cffacc68d8d
    14 anzsrc-for:11
    15 anzsrc-for:1103
    16 anzsrc-for:1108
    17 anzsrc-for:1109
    18 schema:author Nbf3800d64e7547a99ee3ee65ad7c4aa5
    19 schema:datePublished 1998-01
    20 schema:datePublishedReg 1998-01-01
    21 schema:description Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, due to the diffuse infiltrative nature of primary glial tumor cell growth. Whether ultimate effect moieties are immunoglobulins, fragments and/or their constructs with drugs, toxins, radionuclides, or immune cells, the specificity of effector: cell surface marker is crucial. This review describes the identification, immunologic characterization, and biologic behavior of a transmembrane tumor-specific altered growth factor receptor molecule which may well serve as a mediator of multiple immunotherapeutic approaches: the class III variant of the epidermal growth factor receptor, EGFRvIII.
    22 schema:genre article
    23 schema:inLanguage en
    24 schema:isAccessibleForFree false
    25 schema:isPartOf N5b6e0e8f91a84a79ab297e4d09ea57d3
    26 N6f8b550ab80e47b8ad7b90934f2610f0
    27 sg:journal.1114176
    28 schema:keywords EGFRvIII
    29 III variant
    30 approach
    31 behavior
    32 biologic behavior
    33 cancer cell eradication
    34 cell eradication
    35 cell growth
    36 cell surface markers
    37 cells
    38 central nervous system
    39 characterization
    40 class III variants
    41 constructs
    42 diffuse infiltrative nature
    43 distinction
    44 drugs
    45 effect moieties
    46 effectors
    47 epidermal growth factor receptor
    48 eradication
    49 factor receptor
    50 factor receptor molecule
    51 fragments
    52 glial tumor cell growth
    53 growth
    54 growth factor receptor
    55 growth factor receptor molecule
    56 identification
    57 immune cells
    58 immunoglobulin
    59 immunologic characterization
    60 immunotherapeutic approaches
    61 immunotherapeutic target
    62 infiltrative nature
    63 markers
    64 mediators
    65 moiety
    66 molecules
    67 multiple immunotherapeutic approaches
    68 nature
    69 neoplastic cells
    70 nervous system
    71 normal tissues
    72 primary glial tumor cell growth
    73 radionuclides
    74 receptor molecules
    75 receptors
    76 recognition
    77 review
    78 sparing
    79 specific recognition
    80 specificity
    81 specificity of effector
    82 surface markers
    83 system
    84 target
    85 tissue
    86 toxin
    87 tumor cell growth
    88 ultimate effect moieties
    89 utilization
    90 variants
    91 schema:name The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
    92 schema:pagination 148-58
    93 schema:productId N40adc34df51f41178bf59470e78ff5c1
    94 N5786672ea5214ae48abb18bce71f1beb
    95 N6cbc7f2557484862a180664d6879de66
    96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070986052
    97 https://doi.org/10.3109/13550289809114515
    98 schema:sdDatePublished 2021-11-01T18:00
    99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    100 schema:sdPublisher Nbd998e721bd34bc9946f5049b0b69bf8
    101 schema:url https://doi.org/10.3109/13550289809114515
    102 sgo:license sg:explorer/license/
    103 sgo:sdDataset articles
    104 rdf:type schema:ScholarlyArticle
    105 N0c4f6fa5387a4867b15f30048c91cbfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Immunotherapy
    107 rdf:type schema:DefinedTerm
    108 N18c8c6c0ba874c5fb761e7ef0dc66e11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Microscopy, Fluorescence
    110 rdf:type schema:DefinedTerm
    111 N202177ade7b74d38b89b07b2f2fc744a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name ErbB Receptors
    113 rdf:type schema:DefinedTerm
    114 N20c93655b5244d43aea31df0ba7af6e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Glioma
    116 rdf:type schema:DefinedTerm
    117 N27f893b83a974c08ab5fc474876a300c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Humans
    119 rdf:type schema:DefinedTerm
    120 N40adc34df51f41178bf59470e78ff5c1 schema:name dimensions_id
    121 schema:value pub.1070986052
    122 rdf:type schema:PropertyValue
    123 N55513decefe24d48942bee497224b4e3 rdf:first sg:person.01273435474.61
    124 rdf:rest Nb619bc15a967463dbc12d32ae5469950
    125 N5786672ea5214ae48abb18bce71f1beb schema:name doi
    126 schema:value 10.3109/13550289809114515
    127 rdf:type schema:PropertyValue
    128 N5b6e0e8f91a84a79ab297e4d09ea57d3 schema:volumeNumber 4
    129 rdf:type schema:PublicationVolume
    130 N64bf6d5c2b1e4431ac0d39756a3a2a65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Immunohistochemistry
    132 rdf:type schema:DefinedTerm
    133 N6cbc7f2557484862a180664d6879de66 schema:name pubmed_id
    134 schema:value 9584952
    135 rdf:type schema:PropertyValue
    136 N6f8b550ab80e47b8ad7b90934f2610f0 schema:issueNumber 2
    137 rdf:type schema:PublicationIssue
    138 N716aa7f2e81f4ed697f75529f12facb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Animals
    140 rdf:type schema:DefinedTerm
    141 N76260d334f6b474395217f2bab94e487 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Molecular Sequence Data
    143 rdf:type schema:DefinedTerm
    144 N76ed725bd65d4cc9baf62362dfcf0aa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Mice, Nude
    146 rdf:type schema:DefinedTerm
    147 N79cc634ea3c04a1b83ac80eba0cf26ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Mice
    149 rdf:type schema:DefinedTerm
    150 N9c1fc5014528453cb7f6042c9b3cf638 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Antibodies, Monoclonal
    152 rdf:type schema:DefinedTerm
    153 Nb619bc15a967463dbc12d32ae5469950 rdf:first sg:person.014005665777.05
    154 rdf:rest Ne39b19212c4544ab90689c9231638f39
    155 Nbd998e721bd34bc9946f5049b0b69bf8 schema:name Springer Nature - SN SciGraph project
    156 rdf:type schema:Organization
    157 Nbf3800d64e7547a99ee3ee65ad7c4aa5 rdf:first sg:person.01121443024.27
    158 rdf:rest N55513decefe24d48942bee497224b4e3
    159 Nc610f6d282984f4fa20d94ddcf728d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Amino Acid Sequence
    161 rdf:type schema:DefinedTerm
    162 Ndb6551811885463d9e4b0f526d177688 rdf:first sg:person.013515206217.45
    163 rdf:rest rdf:nil
    164 Ne332b1aebde7470e8ef27cffacc68d8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Antigens, Neoplasm
    166 rdf:type schema:DefinedTerm
    167 Ne39b19212c4544ab90689c9231638f39 rdf:first sg:person.01230736174.47
    168 rdf:rest Ndb6551811885463d9e4b0f526d177688
    169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    170 schema:name Medical and Health Sciences
    171 rdf:type schema:DefinedTerm
    172 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Clinical Sciences
    174 rdf:type schema:DefinedTerm
    175 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Medical Microbiology
    177 rdf:type schema:DefinedTerm
    178 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
    179 schema:name Neurosciences
    180 rdf:type schema:DefinedTerm
    181 sg:grant.2441054 http://pending.schema.org/fundedItem sg:pub.10.3109/13550289809114515
    182 rdf:type schema:MonetaryGrant
    183 sg:grant.2465896 http://pending.schema.org/fundedItem sg:pub.10.3109/13550289809114515
    184 rdf:type schema:MonetaryGrant
    185 sg:grant.2468932 http://pending.schema.org/fundedItem sg:pub.10.3109/13550289809114515
    186 rdf:type schema:MonetaryGrant
    187 sg:grant.2634129 http://pending.schema.org/fundedItem sg:pub.10.3109/13550289809114515
    188 rdf:type schema:MonetaryGrant
    189 sg:grant.2634316 http://pending.schema.org/fundedItem sg:pub.10.3109/13550289809114515
    190 rdf:type schema:MonetaryGrant
    191 sg:journal.1114176 schema:issn 1355-0284
    192 1538-2443
    193 schema:name Journal of NeuroVirology
    194 schema:publisher Springer Nature
    195 rdf:type schema:Periodical
    196 sg:person.01121443024.27 schema:affiliation grid-institutes:grid.189509.c
    197 schema:familyName Wikstrand
    198 schema:givenName C J
    199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121443024.27
    200 rdf:type schema:Person
    201 sg:person.01230736174.47 schema:familyName Zalutsky
    202 schema:givenName M R
    203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230736174.47
    204 rdf:type schema:Person
    205 sg:person.01273435474.61 schema:familyName Reist
    206 schema:givenName C J
    207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273435474.61
    208 rdf:type schema:Person
    209 sg:person.013515206217.45 schema:familyName Bigner
    210 schema:givenName D D
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013515206217.45
    212 rdf:type schema:Person
    213 sg:person.014005665777.05 schema:familyName Archer
    214 schema:givenName G E
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014005665777.05
    216 rdf:type schema:Person
    217 grid-institutes:grid.189509.c schema:alternateName Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
    218 schema:name Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
    219 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...